Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: bleomycin sulfate
Biological: filgrastim
Drug: cyclophosphamide
Drug: cytarabine
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: leucovorin calcium
Drug: methotrexate
Drug: prednisone
Drug: trimethoprim-sulfamethoxazole
Drug: vincristine sulfate
Radiation: radiation therapy
Drug: Intrathecal cytarabine

First Posted Date: 2004-05-24

Last Posted Date: 2013-01-24

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 52

Registration Number: NCT00002571

Locations: 🇺🇸
MBCCOP - University of South Alabama, Mobile, Alabama, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 82 locations

Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors

Phase 2

Completed

Conditions: Breast Cancer
Drug/Agent Toxicity by Tissue/Organ
Lung Cancer
Lymphoma
Ovarian Cancer
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-05-24

Last Posted Date: 2011-01-10

Lead Sponsor: Scripps Health

Target Recruit Count: 20

Registration Number: NCT00003269

Locations: 🇺🇸
Scripps Clinic, La Jolla, California, United States

Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-05-21

Last Posted Date: 2011-05-11

Lead Sponsor: Mayo Clinic

Target Recruit Count: 35

Registration Number: NCT00002876

Locations: 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States

Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

First Posted Date: 2004-05-21

Last Posted Date: 2021-02-21

Lead Sponsor: UNICANCER

Target Recruit Count: 216

Registration Number: NCT00003606

Locations: 🇫🇷
Hopital Arnaud de Villeneuve, Montpellier, France

Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2004-05-20

Last Posted Date: 2013-12-19

Lead Sponsor: United Kingdom Children's Cancer Study Group

Target Recruit Count: 100

Registration Number: NCT00003423

Locations: 🇬🇧
Hospital for Sick Children NHS Trust, London, England, United Kingdom

Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: recombinant interleukin-12
Drug: etoposide
Drug: ifosfamide

First Posted Date: 2004-05-20

Last Posted Date: 2013-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00003575

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University Hospital/New Jersey Cancer Center, Newark, New Jersey, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 7 locations

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Drug/Agent Toxicity by Tissue/Organ
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Oral Complications
Radiation Toxicity

First Posted Date: 2004-05-20

Last Posted Date: 2013-06-26

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00004132

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia

Phase 3

Terminated

Conditions: Leukemia

Interventions: Drug: cyclophosphamide
Drug: etoposide
Drug: cyclosporine
Procedure: allogeneic bone marrow transplantation
Radiation: Total Body Irradiation
Drug: methotrexate
Radiation: Radiation
Drug: Busulfan
Drug: Mesna

First Posted Date: 2004-05-19

Last Posted Date: 2013-10-16

Lead Sponsor: Children's Hospital of Philadelphia

Target Recruit Count: 43

Registration Number: NCT00002961

Locations: 🇺🇸
Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States
🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸
Children's Mercy Hospital, Kansas City, Missouri, United States

and more 15 locations

Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: cisplatin
Drug: cyclophosphamide
Drug: etoposide

First Posted Date: 2004-05-17

Last Posted Date: 2012-09-05

Lead Sponsor: Gundersen Lutheran Health System

Target Recruit Count: 8

Registration Number: NCT00083161

Locations: 🇺🇸
Gundersen Lutheran Center for Cancer and Blood, La Crosse, Wisconsin, United States

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

Phase 2

Conditions: Lung Cancer

First Posted Date: 2004-05-17

Last Posted Date: 2011-03-01

Lead Sponsor: American College of Radiology Imaging Network

Target Recruit Count: 250

Registration Number: NCT00083083

Locations: 🇺🇸
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
West Michigan Cancer Center, Kalamazoo, Michigan, United States

and more 46 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy